What Artificial Intelligence Brings To Drug Discovery

What Artificial Intelligence Brings To Drug Discovery – Sanofi Interview

12 May 2017

• By Sten Stovall

By adding another AI deal to Sanofi's innovation quiver, the French group says it's widening its hunt to find single molecules that offer dual or multi-specific targeting to fight disease.

Archery — Sanofi Aims To Use AI To Multi-Target Single Molecules

Sanofi says it aims increasingly to employ artificial intelligence in its quest to find single molecules which can hit more than one disease target, thereby increasing the efficacy of future novel medicines.

Its latest collaboration – announced May 9 with AI specialist Exscientia of Scotland – won't be the company's last in...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Biogen Lays Out Cadence For Felzartamab Data In Kidney Diseases

11 Jun 2025

• By Jessica Merrill

The first Phase III data for the CD38-targeting antibody is expected in 2027 in antibody-mediated rejection in kidney transplant patients, followed by other indications.

Novo Nordisk Teams With Deep Apple On Non-Incretin Obesity Approach

11 Jun 2025

• By Joseph Haas

Novo Nordisk will partner with privately held Deep Apple to study a novel, non-incretin target that could be better suited than GLP-1s for long-term obesity treatment.

Titans Of Pharma: Lilly’s Ricks Tops Big Pharma Pay Chart

11 Jun 2025

• By Eleanor Malone, Edwin Elmhirst, and Kosh Naran

The big pharma CEO with the highest-valued compensation in 2024 was David Ricks of Eli Lilly, while Pfizer and J&J executives slipped into third and fourth place behind AbbVie's now retired chief Richard Gonzalez. European firms brought up the rear.